News
Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...
Estrogen generated in the brain may play a role in regulating appetite, potentially opening new avenues for treating obesity.
While other treatment strategies most often come into play, diet and exercise are the principal staples in the fight against weight gain and obesity. The role of proper nutrition in maintaining a ...
While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...
However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...
A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their ...
Queen Latifah opens up about obesity and heart health risks for public awareness campaign, Truth About Weight.
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback